Commission Regulation (EC) No 1662/2005 of 11 October 2005 amending Annex I of Council Regulation (EC) No 953/2003 to avoid trade diversion into the European Union of certain key medicines

COMMISSION REGULATION (EC) No 1662/2005

of 11 October 2005

amending Annex I of Council Regulation (EC) No 953/2003 to avoid trade diversion into the European Union of certain key medicines

THE COMMISSION OF THE EUROPEAN COMMUNITIES,

Having regard to the Treaty establishing the European Community,

Having regard to Council Regulation (EC) No 953/2003 of 26 May 2003 to avoid trade diversion into the European Union of certain key medicines[(1)], and in particular Article 4(4) and (8) thereof,

Whereas:

(1) The Commission has received modified applications under Article 4 of Regulation (EC) No 953/2003 with respect to *Epivir 150 mg × 60* and *Combivir 300/150 mg × 60*.

(2) The Commission has determined that the applications received fulfil the requirements set out in Regulation (EC) No 953/2003 in accordance with the procedure laid down in Article 5(2) of that Regulation.

(3) The applicants have been informed of the Commission decision to accept their applications.

(4) It is therefore necessary to replace Annex I to Regulation (EC) No 953/2003,

HAS ADOPTED THIS REGULATION:

Article 1

Annex I to Regulation (EC) No 953/2003 is replaced by the Annex to this Regulation.

Article 2

This regulation enters into force on the day following its publication in the *Official Journal of the European Union*.

It shall be binding in its entirety and directly applicable in all Member States.

Changes to legislation: Commission Regulation (EC) No 1662/2005 is up to date with all changes known to be in force on or before 25 February 2022. There are changes that may be brought into force at a future date. Changes that have been made appear in the content and are referenced with annotations. (See end of Document for details) View outstanding changes

Done at Brussels, 11 October 2005.

For the Commission

Peter MANDELSON

Member of the Commission

***Changes to legislation:** Commission Regulation (EC) No 1662/2005 is up to date with all changes known to be in force on or before 25 February 2022. There are changes that may be brought into force at a future date. Changes that have been made appear in the content and are referenced with annotations. (See end of Document for details) View outstanding changes*

ANNEX

Product	**Manufacturer/Country of exporter**	**Distinctive features**	**Date of approval**	**CN/TARIC code**[a]
'TRIZIVIR 750 mg × 60	GLAXO SMITH KLINE GSK House 980 Great West Road BRENTFORD, MIDDX TW8 9GS United Kingdom	Distinctive access pack — tri-lingual text	19.4.2004	3004 90 19
EPIVIR 150 mg × 60	GLAXO SMITH KLINE GSK House 980 Great West Road BRENTFORD, MIDDX TW8 9GS United Kingdom	Distinctive access pack — tri-lingual text — red tablets		3004 90 19
RETROVIR 250 mg × 40	GLAXO SMITH KLINE GSK House 980 Great West Road BRENTFORD, MIDDX TW8 9GS United Kingdom	General export pack (blue) not used in EU. French hospital pack — Francophone markets	19.4.2004	3004 90 19
RETROVIR 300 mg × 60	GLAXO SMITH KLINE GSK House 980 Great West Road BRENTFORD, MIDDX TW8 9GS United Kingdom	General export pack (blue) not used in EU. French hospital pack — Francophone markets	19.4.2004	3004 90 19

Afghanistan
Angola
Armenia
Azerbaijan
Bangladesh
Benin
Bhutan
Botswana
Burkina Faso
Burundi
Cambodia
Cameroon
Cape Verde
Central African Republic
Chad
Comoros
Congo
Côte d'Ivoire
Djibouti
DR Congo
East Timor
Equatorial Guinea
Eritrea
Ethiopia
Gambia
Ghana
Guinea
Guinea Bissau
Haiti
Honduras
India
Indonesia
Kenya
Kiribati
Korea (Dem Rep)
Kyrgyz Republic
Lao People's DR
Lesotho
Liberia
Madagascar

a Only if applicable.'